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Overview of PacELF—the Pacific Programme
for the Elimination of Lymphatic Filariasis
Kazuyo Ichimori1* and Patricia M. Graves2
This special issue of Tropical Medicine and Health has
been produced by the PacELF Endgame project to record
and celebrate the successes of PacELF—the Pacific
Programme for the Elimination of Lymphatic Filariasis.
Lymphatic filariasis (LF) is a nematode worm-caused
infection transmitted by mosquitoes. Male and female
adult worms develop in humans from larvae injected by
mosquitoes of several genera. The worms lodge in the
lymph vessels and nodes, where they mate and live for
several years, producing microfilariae that circulate in
the peripheral blood and can be ingested by mosquitoes
to continue the cycle. Worms in the lymphatic system
contribute to acute attacks of dermatolymphangitis
caused by secondary bacterial infection or lymphangitis
arising from death of worms. Resulting chronic morbidity
can be severe, irreversible, and lifelong, including enlarged
limbs (lymphoedema and elephantiasis) and hydrocoele
(swollen scrotum in men). Filariasis can be treated with
deworming drugs, which are effective at resolving the in-
fection at an early stage, but chronic disabling conse-
quences are harder to address. Hydrocoele can be
resolved by surgery. Interrupting transmission requires
widespread repeated treatment of mostly asymptomatic
people (who may have microfilariae in their blood)
coupled with vector control.
Lymphatic filariasis has long been a highly endemic
scourge in the Pacific, with infection rates amongst the
highest in the world. In this area, all LF is caused by the
species Wuchereria bancrofti, with different ecologies
based on the local mosquito vectors (Anopheles, Culex,
or Aedes) and the periodicity (time when microfilariae
are at highest density in the blood).
Both Japan and Australia had succeeded in interrupting
transmission of LF by the 1970s. Several Pacific countries
had been working more or less independently on LF con-
trol. In Fiji, the late Dr. Mataika and his staff made sub-
stantial progress in mapping and instigating programs in
areas of that country, while in Samoa, the Ministry of
Health supported by WHO conducted annual mass drug
administration with different drug regimens. Mass drug
administration was also conducted to a limited extent in
other countries, including American Samoa and Vanuatu.
In French Polynesia, the Ministry of Health and Institut
Malardé, as a pioneer institute of Pacific filariasis, had also
been very active in LF control and studies.
Despite these excellent efforts, there had really been
no coordinated global or regional plans to control LF.
Then, in 1993, the International Task Force for Disease
Eradication identified lymphatic filariasis as one of only
six eradicable or potentially eradicable diseases. This
conclusion was based on newly available, safe, and cost-
effective control methods, including improved diagnostic
tools, improved drugs and drug combinations, mosquito
control, and effective strategies for dealing with end-
stage disease. In the 1990s, a number of events and ac-
tivities brought LF to a higher profile. The scene was set
for a global effort.
In May 1997, the World Health Assembly (WHA)
passed a resolution urging Member States “to strengthen
activities toward eliminating lymphatic filariasis as a
public health problem, and requesting the Director-
General to mobilize support for global and national
elimination activities.” (WHA Resolution 50.29). These
events served to increase the awareness of the disease as
a public health problem and alerted Pacific Island coun-
tries and territories of the need to control or eliminate
filariasis. In the Pacific region, support had already been
building through two international meetings on lymph-
atic filariasis elimination convened by WHO and James
Cook University (JCU): one in Bali, Indonesia, in 1996
and one in Townsville, Australia, in July 1997 coinciding
with the official opening of the JCU WHO Collaborating
Centre on Control of Lymphatic Filariasis.
In March 1999, a meeting of the Secretariat of the
Pacific Community (SPC) was held in Palau in coordin-
ation with the WHO Pacific Ministers of Health
meeting. The SPC Heads of Health Services Consultative
Meeting took up this call to action and reported in their
resulting statement on Healthy Islands: “In keeping with
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the WHA resolution to eliminate lymphatic filariasis, the
meeting encouraged the Secretariat to continue discus-
sions with WHO, and other relevant donor agencies to
develop and implement a comprehensive strategy to
eliminate lymphatic filariasis in all 22 island countries
and territories.” At this time, both WHO and SPC
were well positioned to work together on LF control.
WHO had vector-borne disease and communicable
diseases experts in Manila, Papua New Guinea (PNG),
Solomon Islands, and Vanuatu. The SPC was imple-
menting the Pacific Regional Vector Borne Diseases
Project and had staff based at SPC HQ in Noumea,
New Caledonia, and project offices in Vanuatu, Solo-
mon Islands, and Fiji.
Dr. Kazuyo Ichimori from WHO and Dr. Tony Stew-
art from SPC subsequently met in Port Vila, Vanuatu, to
discuss how best to enact the resolutions of the WHA in
the region and the regional program initiatives discussed
in Palau in March 1999. Funding was secured from
WHO and through SPC’s vector-borne diseases project
to hold a meeting of Pacific countries in Brisbane on the
28th and 29th June 1999. Participants were public health
leaders from those Pacific countries with recent or
current transmission of lymphatic filariasis, together
with staff from SPC, WHO, and other institutions work-
ing in the field of elimination of filariasis. This meeting
provided a forum for the country representatives from
American Samoa, Cook Islands, Fiji, French Polynesia,
Nauru, New Caledonia, Niue, PNG, Samoa, Solomon
Islands, Tonga, Tuvalu, Vanuatu, and Wallis and Futuna
to discuss current and planned activities globally and
within the Pacific region. Representatives from Univer-
sity of Queensland, James Cook University, SmithKline
Beecham, and AMRAD ICT also participated. The 14
countries attending the meeting refined and endorsed a
regional plan of action, and appointed four country rep-
resentatives to form the interim coordinating body, in
order to facilitate implementation between meetings.
Thus, the world’s first regional LF control program—Pa-
cELF—was born.
Pacific countries and territories represent a subset
of countries in the WHO WPRO region. PacELF was
designed as a regional program driven by the coun-
tries and constituted a network of the 22 island coun-
tries and territories in the Pacific for the sole purpose
of eliminating filariasis in the Pacific. The strategy for
achieving this goal was annual mass drug administra-
tion (MDA) using diethylcarbamazine (DEC) with
albendazole to stop transmission, together with clin-
ical management of infections to minimize progres-
sion of pathology in individuals already infected. Since
1999, PacELF has been supported by many partners in-
cluding WHO, WPRO, Government of Japan, JICA,
AusAID (now DFAT), UK VSO, USAID, New Zealand,
Republic of Korea, the NTD support center at the Task
Force for Global Health, James Cook University, Nagasaki
University, the Centers for Disease Control and Preven-
tion, and GlaxoSmithKline.
At the start of PacELF, 16 of the 22 Pacific countries
and territories were classified as LF endemic through
having prevalence > 1% in at least part of the country.
Mass drug administration (MDA) has been conducted in
15 of these countries (excluding New Caledonia due to
uncertainty about the need for MDA), with the first
starting in 1999. Over the next 18 years, under the
leadership of four different health officers from the
WHO Western Pacific Regional Office [see Table 1], the
program addressed a number of critical issues—often re-
quiring pioneering solutions to problems being faced for
the first time in any of the GPELF countries. These in-
cluded monitoring strategies using sentinel site and spot
check surveys, the routine use of antigen rather than
microfilaria tests, and large population-based surveys
Table 1 PacELF leadership at WHO Division of Pacific Technical
Support, Suva, Fiji, showing major strategies and achievements,
1999 to 2017
1999 to 2005: Dr. Kazuyo Ichimori
• Baseline surveys conducted using ICT
• Established a coordinating body and PacELF office and warehouse
• Established logistics systems for drugs, diagnostics and data
reporting
• Regular program managers’ meetings
• Development of M&E plan using A (baseline), B (sentinel),
C (stop MDA), and D (transmission) surveys; C survey was in all ages
and D survey in children
• First countries stopped MDA in 2004
• Initiated morbidity surveys
• Published PacELF book
2006 to 2008: Dr. Corinne Capuano
• M&E guideline revision—maintained stop MDA (C) surveys in all
ages and transmission surveys in children, with mop up around
positive cases
• Introduced test and treat strategies in three countries
• Improvements to behavior change communication
• Morbidity surveys and hydrocoele surgery programs in Fiji
• Maintained MDA and post-MDA surveillance
2009 to 2011: Dr. Sunghye Kim
• Preparation of elimination dossiers
• Maintained MDA and post-MDA surveillance
2012 to 2017: Dr. Padmasiri Aratchige
• Maintained MDA as needed and oversaw transmission assessment
surveys
• Validation of elimination dossiers approved for Vanuatu, Republic of
Marshall Islands, Niue, Cook Is, and Tonga
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in all ages designed to determine whether MDA
should be stopped. Many countries stopped MDA in
the mid- to late 2000s, although five are continuing to
the present day. The strategies used, monitoring and
elimination guidelines, and status of progress towards
elimination up to 2005 were described in “The PacELF
Way,” a book published in 2006 (http://iris.wpro.
who.int/handle/10665.1/10966). The endemicity status
of countries before PacELF, in 2000 and in 2017, can
be seen in Maps 1, 2, and 3.
Those countries that reduced prevalence low
enough to stop MDA then entered several years of
post-MDA surveillance during which they conducted
further surveys to validate elimination. These surveys
followed a series of guidelines produced by PacELF
and the GPELF that evolved over the years. The ini-
tial PacELF monitoring and evaluation strategy was
developed in 2003, modified in 2008 to include in-
novative test and treat and contact tracing strategies,
and was coordinated with the global strategy using
“Transmission Assessment Surveys” by 2011 (http://
apps.who.int/iris/handle/10665/44580).
For validation, it is required that each country produce
a “dossier” to present the evidence to WHO that LF has
been eliminated as a public health problem. The following
countries have received validation of their dossiers by
2017: Vanuatu, Niue, Cook Islands, Republic of the Mar-
shall Islands, and Tonga. Several others are close to
submitting dossiers. Problems and challenges for the other
countries include the need to rapidly and completely
scale-up interventions, the possibility of resurgence from
remaining LF hotspots of transmission, and the difficulty
of ensuring that those with residual chronic morbidity are
provided with quality services.
To celebrate PacELF and the countries’ achievements
in LF elimination, this special issue reports on the pro-
gress towards LF elimination in selected countries. We
present here maps showing the status of the countries in
the region at three time points: (1) those that were ever
endemic, (2) endemicity at the start of the global pro-
gram (2000), and (3) the status in 2016. The countries
described in this issue include one with highly successful
and rapid progression to validation of LF elimination as
a public health problem (Vanuatu) as well as those with
lingering challenges (Federated States of Micronesia and
American Samoa). Papers from other countries will be
included as elimination is achieved and their dossiers be-
come available. We take the opportunity also to provide
a comprehensive bibliography of published papers on LF
in the Pacific (including Australia and Japan) for future
reference (see Additional file 1).
We hope that these success stories will be both a
source of inspiration to the other regions of the
world also engaged in such effort and a source of jus-
tifiable pride to all the countries and territories in the
Pacific.
Map 1 LF in the Pacific—countries and territories ever endemic
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Map 2 LF in the Pacific—countries and territories endemic in 2000
Map 3 LF in the Pacific—countries and territories endemic in 2017
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Additional file
Additional file 1: Bibliography of published literature on lymphatic
filariasis in the Pacific, Australia, and Japan, 1970 to July 2017. (DOCX 86 kb)
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